OSE Immunotherapeutics
Biotechnology Research in France
Overview
OSE Immunotherapeutics, a biotech dedicated to developing first-in-class assets in immuno-oncology (IO) & immuno-inflammation (I&I).
• Tedopi® (therapeutic cancer vaccine): Registration Phase 3 in 2nd-line NSCLC in HLA-A2+ patients with secondary resistance. Phase 2 trials, sponsored by onco groups, of Tedopi® in combo in solid tumors.
• Lusvertikimab (mAb IL-7R antagonist); Positive Phase 2 in UC; preclinical research in ALL.
• OSE-279 (anti-PD1): 1st positive results in Phase 1/2 in solid tumors.
• FR-104/VEL-101 (anti-CD28 mAb): developed in partnership with Veloxis in transplant; Phase 1/2 in renal transplant (CHU Nantes); successful Phase 1 in the US (Veloxis).
• Anti-SIRPα mAb developed in partnership with Boehringer Ingelheim in advanced solid tumors & cardiovascular-renal-metabolic diseases; positive Phase 1 dose escalation results in monotherapy and combo; Phase 2 in CRM diseases planned end 2024.
• ABBV-230 (ChemR23 agonist mAb) developed in partnership with AbbVie in chronic inflammation.
4 proprietary drug discovery platforms
• Pro-resolutive mAb platform
• Myeloid Checkpoint platform
• BiCKI® Platform
• mRNA Therapeutic platform f
Tagline
Immuno-Oncology and Immuno-Inflammation - Breakthrough Immuno-Science for Patients
EMPLOYEES
51-200 employees
FOUNDED
2012
HQ
NANTES, PAYS DE LA LOIRE
TYPE
Public Company
Location
- Street
- 22, avenue Bénoni Goullin
- City
- NANTES
- Region
- PAYS DE LA LOIRE
- Postal code
- 44200
- Country
- France
Email patterns
See email patterns for OSE Immunotherapeutics
Address formats, how often each is used and the mail provider.
Start for freeTrade fairs
FAQ
What is the company name?
ose-immuno.com is the website of OSE Immunotherapeutics.
What is the industry of the company?
OSE Immunotherapeutics (ose-immuno.com) is in the Biotechnology Research industry.
What products and services does the company offer?
OSE Immunotherapeutics (ose-immuno.com) lists these specialties: Immuno-oncologie, Immunothérapie, Maladies autoimmunes, NSCLC, Checkpoint inhibitor, Développement clinique, Biotechnologie, Néo-épitopes, SIRP-alpha, MDSC, Rectocolite hémorragique, and Polyarthrite rhumatoïde.
When was the company founded?
OSE Immunotherapeutics (ose-immuno.com) was founded in 2012.
How many employees does the company have?
OSE Immunotherapeutics (ose-immuno.com) has 51-200 employees.
What is the company type?
The company type of OSE Immunotherapeutics (ose-immuno.com) is Public Company.
Where is the company headquartered?
OSE Immunotherapeutics (ose-immuno.com) is headquartered in NANTES, PAYS DE LA LOIRE.
What is the address of the company?
The address of OSE Immunotherapeutics (ose-immuno.com) is 22, avenue Bénoni Goullin, NANTES, PAYS DE LA LOIRE, 44200, France.
What are the social media accounts of the company?
The social media account of OSE Immunotherapeutics (ose-immuno.com) is LinkedIn.
Social media